Stay updated on Pembrolizumab in Esophagogastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Esophagogastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Esophagogastric Cancer Clinical Trial page
- Check4 days agoChange DetectedFooter revision updated to v3.4.1, replacing v3.4.0; this is a minor metadata change that does not affect study content or page interactions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoChange DetectedAdded a glossary display option and updated study metadata to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. Removed the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. This appears to be a minor back-end/formatting change and does not modify the study details or content presented on the page.SummaryDifference0.1%

- Check47 days agoChange DetectedFooter now includes Revision: v3.3.3 and removes HHS Vulnerability Disclosure and Revision: v3.3.2. This update does not affect study details or functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedPublications description now states that items are automatically filled from PubMed, and the revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check83 days agoChange DetectedRemoved the general government funding/status notice banner; this site-wide notice did not affect the study details or participation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Esophagogastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Esophagogastric Cancer Clinical Trial page.